Poolbeg Pharma (LON:POLB) Hits New 1-Year Low – Should You Sell?

Posted by Kim Johansen on Mar 31st, 2025

Poolbeg Pharma PLC (LON:POLB – Get Free Report) hit a new 52-week low on Monday . The stock traded as low as GBX 2.70 ($0.03) and last traded at GBX 2.73 ($0.04), with a volume of 636335 shares trading hands. The stock had previously closed at GBX 2.71 ($0.04).

Analysts Set New Price Targets

Separately, Shore Capital reiterated a “house stock” rating on shares of Poolbeg Pharma in a research note on Thursday, January 2nd.

Check Out Our Latest Stock Report on Poolbeg Pharma

Poolbeg Pharma Stock Performance

The business has a 50 day simple moving average of GBX 4.02 and a two-hundred day simple moving average of GBX 6.43. The firm has a market capitalization of £14.03 million, a P/E ratio of 0.00 and a beta of 2.11.

About Poolbeg Pharma

(Get Free Report)

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.